Compare Cytokinetics Inc (CYTK) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.8. The key difference: Cytokinetics Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | MSTU | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $76.30 |
52-Week Low | $34.31 | $1.46 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
MSTU, a leveraged ETF tracking MicroStrategy (MSTR), trades at $1.815, down 3.97% on the day, reflecting severe long-term erosion. The technical outlook is bearish with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights catastrophic losses, including a 98% decline from 2024 levels, exacerbated by a 10:1 reverse stock split effective August 24, 2026.
The outlook for MSTU is highly risky due to leveraged decay and dependency on MSTR's volatile performance. Investment opportunities are minimal given the fund's history of value destruction, with risks including daily rebalancing losses, crypto market exposure, and lack of fundamental company metrics. Caution is paramount for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
